RT Journal Article
SR Electronic
T1 First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e002863
DO 10.1136/jitc-2021-002863
VO 9
IS 8
A1 Piha-Paul, Sarina A
A1 Geva, Ravit
A1 Tan, Tira J
A1 Lim, Darren WT
A1 Hierro, Cinta
A1 Doi, Toshikiko
A1 Rahma, Osama
A1 Lesokhin, Alexander
A1 Luke, Jason John
A1 Otero, Javier
A1 Nardi, Lisa
A1 Singh, Angad
A1 Xyrafas, Alexandros
A1 Chen, Xinhui
A1 Mataraza, Jennifer
A1 Bedard, Philippe L
YR 2021
UL http://jitc.bmj.com/content/9/8/e002863.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.